암 줄기세포 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Cancer Stem Cell Market size is expected to reach USD 5.53 Billion in 2034 from USD 2.26 Billion (2025) growing at a CAGR of 10.43% during 2026-2034.

The global cancer stem cell (CSC) market is emerging as a critical segment within oncology research. Cancer stem cells are believed to contribute to tumor initiation, metastasis, and recurrence, making them a key focus area in next-generation therapeutic development. Pharmaceutical and biotech companies are investing heavily in CSC-targeted drug discovery, while research institutions utilize specialized cell lines and assays for experimental validation.

Technological advancements such as single-cell sequencing, 3D tumor models, and organoid culture systems are strengthening research capabilities. Increasing clinical trials evaluating CSC-targeted therapies are broadening commercial prospects. Rising cancer incidence globally further amplifies demand for advanced treatment solutions.

Future market growth will depend on clinical validation of CSC-based therapies and companion diagnostic tools. Precision medicine strategies integrating CSC biomarkers will enhance treatment efficacy. Collaborations between academic researchers and pharmaceutical firms will accelerate translational progress, positioning CSC research as a central pillar of modern oncology innovation.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Cancer Forms

• Breast
• Blood
• Lung
• Brain
• Colorectal
• Pancreatic
• Bladder
• Liver
• Others

By Application

• Targeted Cancerous Stem Cells
• Stem Cell-based Cancer Therapy

COMPANIES PROFILED

• Merck KGaA, Miltenyi Biotec, Bionomics, AbbVie Inc, Stemline Therapeutics Inc, Thermo Fisher Scientific Inc, MacroGenics Inc, STEMCELL Technologies Inc, FUJIFILM Irvine Scientific, Lineage Cell Therapeutics Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER STEM CELL MARKET: BY CANCER FORMS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Cancer Forms
• 4.2. Breast Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Blood Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Lung Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Brain Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Colorectal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Pancreatic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Bladder Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. Liver Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.10. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER STEM CELL MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Targeted Cancerous Stem Cells Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Stem Cell-based Cancer Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER STEM CELL MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Cancer Forms
  • 6.2.2 By Application
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Cancer Forms
  • 6.3.2 By Application
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Cancer Forms
  • 6.4.2 By Application
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Cancer Forms
  • 6.5.2 By Application
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Cancer Forms
  • 6.6.2 By Application
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL CANCER STEM CELL INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Merck KGaA
  • 8.2.2 Miltenyi Biotec
  • 8.2.3 Bionomics
  • 8.2.4 AbbVie Inc
  • 8.2.5 Stemline Therapeutics Inc
  • 8.2.6 Thermo Fisher Scientific Inc
  • 8.2.7 MacroGenics Inc
  • 8.2.8 STEMCELL Technologies Inc
  • 8.2.9 FUJIFILM Irvine Scientific
  • 8.2.10 Lineage Cell Therapeutics Inc